| . | Arm 1 N = 63 . | Arm 2 N = 39 . | P value . |
|---|---|---|---|
| Median age—years (range) | 69 (38-86) | 70 (51-87) | .58 |
| Median weight, kg (range) | 74 (40-131) | 74 (51-145) | .36 |
| Median height, cm (range) | 170 (145-190.5) | 167.6(149-188) | .41 |
| Sex—male (%) | 36/63 (56.5) | 20/39 (50) | .56 |
| Race (%) | |||
| African American | 29 (46) | 25 (64) | .08 |
| White | 30 (48) | 8 (21) | .01 |
| Hispanic | 2 (3.2) | 3 (7.7) | .92 |
| Asian | 1 (1.6) | 1 (2.5) | .73 |
| Other | 1 (1.6) | 2 (5.1) | .30 |
| Prior Dara-IV exposure (%) | 33/63 (52) | 4/39 (10) | .02 |
| Transition Dara-IV to SQ < 3 months (%) | 22/63 (35) | 0/39 (0) | .00003 |
| Newly diagnosed (%) | 13/63 (21) | 16/39 (47) | .03 |
| C1D1 acetaminophen (%) | 63/63 (100) | 39/39 (100) | 1 |
| C1D1 diphenhydramine (%) | 62/63 (98) | 39/39 (100) | .39 |
| C1D1 montelukast (%) | 59/63 (94) | 39/39 (100) | .30 |
| C1D1 dexamethasone (%) | 63/63 (100) | 39/39 (100) | 1 |
| . | Arm 1 N = 63 . | Arm 2 N = 39 . | P value . |
|---|---|---|---|
| Median age—years (range) | 69 (38-86) | 70 (51-87) | .58 |
| Median weight, kg (range) | 74 (40-131) | 74 (51-145) | .36 |
| Median height, cm (range) | 170 (145-190.5) | 167.6(149-188) | .41 |
| Sex—male (%) | 36/63 (56.5) | 20/39 (50) | .56 |
| Race (%) | |||
| African American | 29 (46) | 25 (64) | .08 |
| White | 30 (48) | 8 (21) | .01 |
| Hispanic | 2 (3.2) | 3 (7.7) | .92 |
| Asian | 1 (1.6) | 1 (2.5) | .73 |
| Other | 1 (1.6) | 2 (5.1) | .30 |
| Prior Dara-IV exposure (%) | 33/63 (52) | 4/39 (10) | .02 |
| Transition Dara-IV to SQ < 3 months (%) | 22/63 (35) | 0/39 (0) | .00003 |
| Newly diagnosed (%) | 13/63 (21) | 16/39 (47) | .03 |
| C1D1 acetaminophen (%) | 63/63 (100) | 39/39 (100) | 1 |
| C1D1 diphenhydramine (%) | 62/63 (98) | 39/39 (100) | .39 |
| C1D1 montelukast (%) | 59/63 (94) | 39/39 (100) | .30 |
| C1D1 dexamethasone (%) | 63/63 (100) | 39/39 (100) | 1 |
Abbreviations: C, cycle; D, day; Dara-IV exposure, any previous intravenous daratumumab given.
Arm 1, pre-interventional; Arm 2, post-interventional.
| . | Arm 1 N = 63 . | Arm 2 N = 39 . | P value . |
|---|---|---|---|
| Median age—years (range) | 69 (38-86) | 70 (51-87) | .58 |
| Median weight, kg (range) | 74 (40-131) | 74 (51-145) | .36 |
| Median height, cm (range) | 170 (145-190.5) | 167.6(149-188) | .41 |
| Sex—male (%) | 36/63 (56.5) | 20/39 (50) | .56 |
| Race (%) | |||
| African American | 29 (46) | 25 (64) | .08 |
| White | 30 (48) | 8 (21) | .01 |
| Hispanic | 2 (3.2) | 3 (7.7) | .92 |
| Asian | 1 (1.6) | 1 (2.5) | .73 |
| Other | 1 (1.6) | 2 (5.1) | .30 |
| Prior Dara-IV exposure (%) | 33/63 (52) | 4/39 (10) | .02 |
| Transition Dara-IV to SQ < 3 months (%) | 22/63 (35) | 0/39 (0) | .00003 |
| Newly diagnosed (%) | 13/63 (21) | 16/39 (47) | .03 |
| C1D1 acetaminophen (%) | 63/63 (100) | 39/39 (100) | 1 |
| C1D1 diphenhydramine (%) | 62/63 (98) | 39/39 (100) | .39 |
| C1D1 montelukast (%) | 59/63 (94) | 39/39 (100) | .30 |
| C1D1 dexamethasone (%) | 63/63 (100) | 39/39 (100) | 1 |
| . | Arm 1 N = 63 . | Arm 2 N = 39 . | P value . |
|---|---|---|---|
| Median age—years (range) | 69 (38-86) | 70 (51-87) | .58 |
| Median weight, kg (range) | 74 (40-131) | 74 (51-145) | .36 |
| Median height, cm (range) | 170 (145-190.5) | 167.6(149-188) | .41 |
| Sex—male (%) | 36/63 (56.5) | 20/39 (50) | .56 |
| Race (%) | |||
| African American | 29 (46) | 25 (64) | .08 |
| White | 30 (48) | 8 (21) | .01 |
| Hispanic | 2 (3.2) | 3 (7.7) | .92 |
| Asian | 1 (1.6) | 1 (2.5) | .73 |
| Other | 1 (1.6) | 2 (5.1) | .30 |
| Prior Dara-IV exposure (%) | 33/63 (52) | 4/39 (10) | .02 |
| Transition Dara-IV to SQ < 3 months (%) | 22/63 (35) | 0/39 (0) | .00003 |
| Newly diagnosed (%) | 13/63 (21) | 16/39 (47) | .03 |
| C1D1 acetaminophen (%) | 63/63 (100) | 39/39 (100) | 1 |
| C1D1 diphenhydramine (%) | 62/63 (98) | 39/39 (100) | .39 |
| C1D1 montelukast (%) | 59/63 (94) | 39/39 (100) | .30 |
| C1D1 dexamethasone (%) | 63/63 (100) | 39/39 (100) | 1 |
Abbreviations: C, cycle; D, day; Dara-IV exposure, any previous intravenous daratumumab given.
Arm 1, pre-interventional; Arm 2, post-interventional.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
